CELG Key Stats
- bluebird bio (BLUE) IPO Opens Sharply Higher Street Insider 10:28 AM
- 5 Stocks the Pros Love This Summer 5:47 AM
- Bluebird: A Hot Biotech IPO Lacking Human Clinical Data 4:30 AM
- Dividends, Schmividends Fool Jun 18
- Good News for Celgene's Pipeline Jun 18
- Early Glance: Biotechnology companies Jun 18
- Good News for Celgene's Pipeline - Analyst Blog Zacks Jun 18
- [video] Drugs IPOs Depend on Deals Jun 18
- [$$] Credits & Debits | firstname.lastname@example.org The Wall Street Journal Jun 18
- Celgene Corporation (CELG): Today's Featured Health Care Laggard Jun 17
CELG Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Celgene Corporation is up 77.58% over the last year vs S&P 500 Total Return up 23.89%, Amgen up 40.29%, and Gilead Sciences up 102.6%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for CELG
Pro Report PDF for CELG
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download CELG Pro Report PDF
Pro Strategies Featuring CELG
Did Celgene Corporation make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Celgene Corporation is a manufacturer of drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major products are Thalamid (thalidomide), which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum ("ENL"), as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and Revlimid (lenalidomide), for which the company has received FDA and EMEA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Both Thalamid and Revlimid are sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Celgene Corporation has strategic collaboration with Acceleron Pharma, Inc. The company was founded in 1980.